Inhibition of N-Type Calcium Channels by Fluorophenoxyanilide Derivatives

Ellen Gleeson; Janease Graham; Sandro Spiller; Irina Vetter; Richard Lewis; Peter Duggan; Kellie Tuck

doi:10.3390/md13042030

Inhibition of N-Type Calcium Channels by Fluorophenoxyanilide Derivatives

Ellen Gleeson, Janease Graham, Sandro Spiller, Irina Vetter, Richard Lewis, Peter Duggan, Kellie Tuck

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Ca_v2.2 channel is a validated target for the treatment of refractory chronic pain. Despite being significantly less complex than the originally designed mimetics, up to a seven-fold improvement in activity was observed.

Original language	English
Pages (from-to)	2030-2045
Number of pages	16
Journal	Marine Drugs
Volume	13
Issue number	4
DOIs	https://doi.org/10.3390/md13042030
Publication status	Published - 1 Apr 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cav2.2
Channel blocker
FLIPR
N-type calcium channel
Pain

Access to Document

10.3390/md13042030

Cite this

@article{1dd6a7e6aa174e419d129154f0eb4b7b,

title = "Inhibition of N-Type Calcium Channels by Fluorophenoxyanilide Derivatives",

abstract = "A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Cav2.2 channel is a validated target for the treatment of refractory chronic pain. Despite being significantly less complex than the originally designed mimetics, up to a seven-fold improvement in activity was observed.",

keywords = "Cav2.2, Channel blocker, FLIPR, N-type calcium channel, Pain",

author = "Ellen Gleeson and Janease Graham and Sandro Spiller and Irina Vetter and Richard Lewis and Peter Duggan and Kellie Tuck",

year = "2015",

month = apr,

day = "1",

doi = "10.3390/md13042030",

language = "English",

volume = "13",

pages = "2030--2045",

journal = "Marine Drugs",

issn = "1660-3397",

publisher = "MDPI",

number = "4",

}

TY - JOUR

T1 - Inhibition of N-Type Calcium Channels by Fluorophenoxyanilide Derivatives

AU - Gleeson, Ellen

AU - Graham, Janease

AU - Spiller, Sandro

AU - Vetter, Irina

AU - Lewis, Richard

AU - Duggan, Peter

AU - Tuck, Kellie

PY - 2015/4/1

Y1 - 2015/4/1

N2 - A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Cav2.2 channel is a validated target for the treatment of refractory chronic pain. Despite being significantly less complex than the originally designed mimetics, up to a seven-fold improvement in activity was observed.

AB - A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Cav2.2 channel is a validated target for the treatment of refractory chronic pain. Despite being significantly less complex than the originally designed mimetics, up to a seven-fold improvement in activity was observed.

KW - Cav2.2

KW - Channel blocker

KW - FLIPR

KW - N-type calcium channel

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=84928342358&partnerID=8YFLogxK

U2 - 10.3390/md13042030

DO - 10.3390/md13042030

M3 - Article

SN - 1660-3397

VL - 13

SP - 2030

EP - 2045

JO - Marine Drugs

JF - Marine Drugs

IS - 4

ER -

Inhibition of N-Type Calcium Channels by Fluorophenoxyanilide Derivatives

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this